FDA Approves Tadalafil Application ANDA210329 by Jubilant Generics
The FDA has approved the original application ANDA210329 for Tadalafil submitted by Jubilant Generics.
Asset / Drug
Drug and asset intelligence for Tadalafil with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
PDE5 Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.